Comorbidities of HIV Infection and Health Care Seeking Behavior Among HIV Infected Patients Attending Public Sector Healthcare Facilities in KwaZulu-Natal: A Cross Sectional Study
Overview
Authors
Affiliations
Background: HIV-infected people may present with co-infections, comorbidities, and side effects associated with antiretroviral therapy. This study explored the prevalence of comorbid health problems and determined the extent of the use of traditional medicine for treatment of co-infections, comorbidities of HIV infection and side effects.
Methods: A cross sectional study, using researcher-administered questionnaires, was carried out among HIV-infected patients in eight public sector healthcare facilities in KwaZulu-Natal between April and October 1024. Self-reports of comorbidities, co-infections and side effects were analyzed with respect to factors such as age, gender, race, and health care seeking behavior including the use of traditional medicine. Cross-tabulations were conducted to test the association between factors and the use of traditional medicine, using Pearson chi-squared (χ2) test. Simple and multiple logistic regression models tested the association of the use of traditional medicine with age, gender, race, side effects and comorbidities. Odds ratios with 95% confidence intervals were estimated. Missing values were handled, defined and treated as missing values in the final analysis.
Results: Overall, 29.5% (n = 516) of the survey participants reported having other comorbidities and or co-infections besides their HIV condition. Same participants reported two or more comorbidities. Almost forty percent of participants (208/531, 39.17%) reported having hypertension as the most noninfectious comorbidity while 21.65% of participants (115/531) had tuberculosis accounting for the most infectious comorbidity. Almost eight percent of participants (142/1748, 8.12%) reported using traditional medicine after starting with cART. Sixty out of 142 participants (60/142, 42.25%) on cART resorted to the use of traditional medicine for the management of comorbidities and or co-infections of their HIV infection. Overall, 311 out of 1748 participants (17.80%) complained of ARVs related side-effects. Forty-five percent of those with side-effects (141/311, 45.34%) reported taking various types of medicines for treating side-effects, with 90.07% of them (127/141) using medicines prescribed by biomedically trained doctors or by pharmacy personnel as over-the -counter medicines, p <0. 001. Very few participants (14/141, 9.93%) resorted to the use of traditional medicine for treating side effects associated with antiretroviral therapy with no significant difference (p=0.293). In a multiple logistic regression, after adjusting for age, gender, race and side-effects due to antiretroviral therapy, odds for using traditional medicine were almost two times higher [odds ratio = 1.884, 95% Confidence Interval 1.317-2.695] with those participants having comorbidities and co-infections, with a significant difference p-value< 0.001.
Conclusions: Comorbidities, co-infections and side effects are prevalent among HIV-infected patients attending public sector healthcare facilities. Odds of using traditional medicine were almost two times higher and significantly associated with the presence of comorbidities and co-infections than for other factors. The presence of such comorbid health problems does not explain the increased use of traditional medicine among HIV-infected patients on antiretroviral therapy. Findings from this study should be interpreted cautiously as they cannot be generalized to the entire population of HIV-infected patients in KwaZulu-Natal. Studies on safety and efficacy of herbal traditional medicines are needed for beneficiation of the minority of patients who still resort to them for co-treatment with combination antiretroviral therapy.
Yimam W, Prem K, Anteneh S, Wolie H Heliyon. 2024; 10(3):e25205.
PMID: 38322839 PMC: 10845723. DOI: 10.1016/j.heliyon.2024.e25205.
Nasir A, Yusuf A, Makhfudli , Harianto S, Okviasanti F, Kartini Y PLoS One. 2023; 18(2):e0282049.
PMID: 36812224 PMC: 9946244. DOI: 10.1371/journal.pone.0282049.
Godongwana M, De Wet-Billings N Heliyon. 2021; 7(8):e07750.
PMID: 34430739 PMC: 8365442. DOI: 10.1016/j.heliyon.2021.e07750.
Godongwana M, De Wet-Billings N, Milovanovic M BMC Health Serv Res. 2021; 21(1):647.
PMID: 34217285 PMC: 8254615. DOI: 10.1186/s12913-021-06670-3.
Butler K, Anderson S, Hayward O, Jacob I, Punekar Y, Evitt L J Manag Care Spec Pharm. 2021; 27(7):891-903.
PMID: 34185564 PMC: 10391195. DOI: 10.18553/jmcp.2021.27.7.891.